THE SMART SOLUTION FOR
INFECTIOUS DISEASE DRUG
ANIMAL MODELS OF DISEASE
There is an increasing demand for the development of novel effective anti-microbial therapeutics. This demand is driven by both the appearance of novel infectious disease agents and the global emergence of life-threatening multidrug-resistant infectious agents arising primarily due to the over use of antibiotics. Noble’s expertise in animal models can be leveraged to study the efficacy of candidate drugs, explore drug toxicity and validate biomarkers.
Nobel Life Sciences provides a panel of optimized animal models to screen new antiviral and antibacterial agents against infectious and resistant pathogens. The use of these models is based on their effectiveness and acceptability within the scientific literature for the development of anti-infectious drugs. End-points can include in vivo physiological measurements, and/or quantification of the infectious agent within the treated animal, and may be coupled with PK/PD analysis.
Nobel Life Sciences can also work with clients as a dedicated arm of your drug discovery team to develop and implement new animal models of infection for the development of novel anti-infectious agents.
Our extensive range of models includes:
- Cotton Rat Influenza Model
- Cotton Rat RSV Model
- Neutropenic Thigh Model
- Non-Surgical Sepsis Model
- MRSA Peritonitis-Sepsis Model
- Tumor Xenograft Models
- Breast Adenocarcinoma Model
- Surgical Adhesion Model
We have experience with a variety of mammalian species used for vaccine and drug development. Our studies range from single digit to hundreds of animals.
Our scientists, with over 15 years of GLP experience, provide all aspects of the GLP process from design to regulatory support of your IND, IDE or PMA FDA submission.